Arena Pharmaceuticals
Arena is now part of Pfizer.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD9.1b (Public information from Dec 2021)
Share price
$99.99 ARNA
San Diego California (HQ)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 19.1m | 16.4m | 733m | - | - | 4.5m | - |
% growth | - | (14 %) | 4378 % | - | - | - | - |
EBITDA | (68.2m) | (128m) | 455m | (385m) | (556m) | (547m) | (519m) |
% EBITDA margin | (357 %) | (783 %) | 62 % | - | - | (12040 %) | - |
Profit | (82.7m) | (26.4m) | 362m | (368m) | (560m) | (545m) | (505m) |
% profit margin | (433 %) | (161 %) | 49 % | - | - | (11980 %) | - |
EV / revenue | 54.7x | 100.9x | 2.0x | - | - | 1065.0x | - |
EV / EBITDA | -15.3x | -12.9x | 3.2x | -8.0x | -8.5x | -8.8x | - |
R&D budget | 43.0m | 90.0m | 200m | - | - | - | - |
R&D % of revenue | 225 % | 550 % | 27 % | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $35.0m | Early VC | |
N/A | $152m | Post IPO Equity | |
$35.5m | Post IPO Equity | ||
N/A | $33.0m | Post IPO Equity | |
N/A | $79.4m | Post IPO Equity | |
* | $6.7b Valuation: $6.7b -15.8x EV/LTM EBITDA | Acquisition | |
Total Funding | CAD47.7m |
Related Content
Recent News about Arena Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.